terfenadine has been researched along with Pregnancy in 9 studies
Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fexofenadine hydrochloride is a frequently used drug for treatment of allergic conditions during pregnancy, but the fetal safety of fexofenadine use has not been well studied." | 7.96 | Association Between Fexofenadine Use During Pregnancy and Fetal Outcomes. ( Andersen, JT; Andersson, NW; Torp-Pedersen, C, 2020) |
| "We sought to determine whether terfenadine use during pregnancy is associated with an increased risk of major malformations, decreased birth weight, perinatal complications, or developmental delays." | 7.70 | Pregnancy outcome after gestational exposure to terfenadine: A multicenter, prospective controlled study. ( Addis, A; Bonati, M; Costa, A; Koren, G; Lalkin, A; Lalkin, I; Loebstein, R, 1999) |
| "Fexofenadine hydrochloride is a frequently used drug for treatment of allergic conditions during pregnancy, but the fetal safety of fexofenadine use has not been well studied." | 3.96 | Association Between Fexofenadine Use During Pregnancy and Fetal Outcomes. ( Andersen, JT; Andersson, NW; Torp-Pedersen, C, 2020) |
| "Fluoxetine, antidepressant widely-used during pregnancy, is a selective inhibitor for P-glycoprotein (P-gp)." | 3.96 | Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics. ( Cavalli, RC; Duarte, G; Lanchote, VL; Moisés, ECD; Moreira, FL; Nardotto, GHB; Pinto, L, 2020) |
| "We sought to determine whether terfenadine use during pregnancy is associated with an increased risk of major malformations, decreased birth weight, perinatal complications, or developmental delays." | 3.70 | Pregnancy outcome after gestational exposure to terfenadine: A multicenter, prospective controlled study. ( Addis, A; Bonati, M; Costa, A; Koren, G; Lalkin, A; Lalkin, I; Loebstein, R, 1999) |
| "Fexofenadine is a well-identified in vivo probe substrate of P-glycoprotein (P-gp) and/or organic anion transporting polypeptide (OATP)." | 1.62 | Chiral Transplacental Pharmacokinetics of Fexofenadine: Impact of P-Glycoprotein Inhibitor Fluoxetine Using the Human Placental Perfusion Model. ( Bapat, P; Berger, H; de Carvalho Cavalli, R; de Lima Moreira, F; Koren, G; Lanchote, VL; Lubetsky, A; Pinto, L, 2021) |
| " Oral LD50 values were approximately 5000 mg/kg in mature mice and rats; intraperitoneal and intravenous values could not be established because of the low solubility of the compound." | 1.26 | Preclinical safety studies with terfenadine. ( Gibson, JP; Huffmann, KW; Newberne, JW, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Pinto, LSR | 1 |
| Vale, GTD | 1 |
| Moreira, FL | 2 |
| Marques, MP | 1 |
| Coelho, EB | 1 |
| Cavalli, RC | 2 |
| Lanchote, VL | 3 |
| Andersson, NW | 1 |
| Torp-Pedersen, C | 1 |
| Andersen, JT | 1 |
| Pinto, L | 2 |
| Nardotto, GHB | 1 |
| Moisés, ECD | 1 |
| Duarte, G | 1 |
| Bapat, P | 1 |
| de Lima Moreira, F | 1 |
| Lubetsky, A | 1 |
| de Carvalho Cavalli, R | 1 |
| Berger, H | 1 |
| Koren, G | 2 |
| Pyzlak, M | 1 |
| Szewczyk, G | 1 |
| Szukiewicz, D | 1 |
| Szczesniak, A | 1 |
| Gibson, JP | 1 |
| Huffmann, KW | 1 |
| Newberne, JW | 1 |
| Li, AP | 1 |
| Jurima-Romet, M | 1 |
| Loebstein, R | 1 |
| Lalkin, A | 1 |
| Addis, A | 1 |
| Costa, A | 1 |
| Lalkin, I | 1 |
| Bonati, M | 1 |
| Lantin, JP | 1 |
| Pécoud, A | 1 |
1 review available for terfenadine and Pregnancy
| Article | Year |
|---|---|
Overview: pharmacokinetic drug-drug interactions.
Topics: Arabinofuranosyluracil; Contraceptives, Oral; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 E | 1997 |
8 other studies available for terfenadine and Pregnancy
| Article | Year |
|---|---|
Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study.
Topics: Adult; Anti-Allergic Agents; Chromatography, High Pressure Liquid; Female; Humans; Plasma; Pregnancy | 2020 |
Association Between Fexofenadine Use During Pregnancy and Fetal Outcomes.
Topics: Adult; Female; Follow-Up Studies; Histamine H1 Antagonists, Non-Sedating; Humans; Infant, Newborn; I | 2020 |
Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics.
Topics: Adult; Antidepressive Agents, Second-Generation; ATP Binding Cassette Transporter, Subfamily B; Case | 2020 |
Chiral Transplacental Pharmacokinetics of Fexofenadine: Impact of P-Glycoprotein Inhibitor Fluoxetine Using the Human Placental Perfusion Model.
Topics: Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Drug Interactions; Female; Fluoxeti | 2021 |
Histamine influence on apoptosis in trophoblast cell cultures.
Topics: Adult; Anti-Inflammatory Agents; Apoptosis; Cell Differentiation; Cells, Cultured; Dexamethasone; En | 2010 |
Preclinical safety studies with terfenadine.
Topics: Animals; Benzhydryl Compounds; Carcinogens; Dogs; Female; Histamine H1 Antagonists; Lethal Dose 50; | 1982 |
Pregnancy outcome after gestational exposure to terfenadine: A multicenter, prospective controlled study.
Topics: Adult; Anti-Asthmatic Agents; Case-Control Studies; Female; Follow-Up Studies; Gestational Age; Hist | 1999 |
[Optimal use of antihistaminics].
Topics: Astemizole; Asthma; Benzhydryl Compounds; Benzimidazoles; Female; Histamine H1 Antagonists; Humans; | 1989 |